Ascendis Pharma to Present Early Data from Achondroplasia Trial at ESPE 2026

COPENHAGEN, Denmark, Sept. 07, 2026 /CourierPR/ -- Ascendis Pharma A/S, a global biopharmaceutical company, will present new data from its endocrinology rare disease programs at the European Society for Paediatric Endocrinology (ESPE) annual congress in Marseille, France, from September 8 to 10, 2026. The company's presentation will focus on early results from the pivotal reACHin Trial of TransCon CNP (navepegritide), a treatment for infants with achondroplasia aged 0 to 2 years.

According to Aimee Shu, M.D., Executive Vice President and Chief Medical Officer at Ascendis Pharma, the company is excited to showcase these findings. "Ascendis is building leadership with its growing portfolio of treatments for individuals with hypoparathyroidism and growth disorders, which we look forward to highlighting at ESPE 2026," Shu stated.

The reACHin Trial aims to evaluate the safety and efficacy of TransCon CNP in infants with achondroplasia. Early data from the first sentinel cohort will be presented at the congress, potentially offering insights into the potential benefits of early medical intervention with TransCon CNP. Shu added, "We believe early medical intervention with TransCon CNP in these youngest children may help mitigate the neuromusculoskeletal complications and co-morbidities associated with this condition."

Ascendis Pharma’s portfolio includes treatments for various endocrine disorders, and the company continues to develop innovative therapies using its TransCon technology platform. The company’s TransCon technology is designed to improve the delivery and effectiveness of therapeutic proteins, potentially leading to better patient outcomes.

At the ESPE congress, Ascendis Pharma will also present other updates related to its endocrinology rare disease programs. These presentations will further underscore the company’s commitment to addressing unmet medical needs in this field. The congress provides a platform for healthcare professionals, researchers, and industry leaders to discuss the latest advancements and challenges in pediatric endocrinology.

Shu concluded, "We are eager to share these early data and the potential benefits of TransCon CNP with the broader medical community. Our goal is to contribute to the ongoing improvement of care for individuals with these rare conditions."

The reACHin Trial is part of Ascendis Pharma’s ongoing efforts to develop and expand its pipeline of treatments. The company continues to invest in research and development, aiming to bring innovative therapies to patients in need.